Cullinan Oncology, Inc. entered into a License and Collaboration Agreement with Harbour BioMed US Inc. for the development and commercialization of HBM7008 in the U.S., with milestone payments and royalties involved. The company also updated its cash runway guidance, expecting its current cash resources to last into 2026.